waldenirb

Home · Newsletter

Retrospective chart reviews and existing data at Walden: when it's human-subjects research and what the IRB needs

"The data already exists, so there are no participants" is the sentence this desk corrects most often. Under the federal rule, people whose records you study are human subjects whenever their identity can readily be reached from what you hold — and a chart is the regulation's own example of information a person expects to stay private. At Walden the question never rests with you anyway: the university sends every project through ethics review, records-based or not, and the board's reading of your data source decides which path the file takes. What you control is whether the file answers the identifiability question, the HIPAA question, and the paperwork question before the board has to ask them.

Cecilia Whitmore, PhD · 2026-08-23

Existing records are human-subjects research when identities can readily be reached from the data. Walden reviews every project regardless, so the board — not you — makes the call. Your file must name who holds identifiers, the site's HIPAA path, and who signs its paperwork.

Why does a project with no participants still go to the board?

Two rules stack here, one federal and one Walden's own. The federal rule sits in 45 CFR 46.102: a human subject includes a living person about whom a researcher obtains or analyzes identifiable private information, and private information covers what a person has "provided for specific purposes" with a reasonable expectation it stays out of public view — the regulation names a medical record as its example. You never meet the patient; the chart still carries the person.

Walden's rule is broader and blunter. The university's handbook requires review of research involving access, collection, or analysis of data from "records of any type," states that ethics review applies "whether human subjects are involved or not," and reserves the exemption from submission to exactly two categories: literature reviews and hypothetical designs. It adds that "no member of the university community may commence any such research data collection until it has been approved by the IRB." So the practical answer to "does my chart review need to go in?" is yes — always. The open questions are which determination comes back and how much the file must carry, and those are worth settling honestly before a document is drafted. The full sequence around the review sits in our walk-through of Walden's IRB process step by step.

Identifiable to whom? The question that decides everything

The regulation's test for identifiability is about reach, not intent: information is identifiable when the identity "is or may readily be ascertained by the investigator or associated with the information." Read that against your actual arrangement, not your hopes for it. The determinations differ sharply:

  1. You open the charts yourself. You can read names and record numbers, so identities are within your reach even if you copy none of them down. This is human-subjects research; the file must say why you need that access, what you record, and how the extraction sheet is kept clean of identifiers.
  2. Someone at the site abstracts the data and hands you a coded set. The federal government's guidance on coded private information defines coding as replacement of identifying details with a number, letter or symbol while "a key to decipher the code exists, enabling linkage of the identifying information to the private information." Whether that still makes you a human-subjects researcher depends on whether you can reach the key. If the site keeps it under a written arrangement that bars release to you in all circumstances, the work may fall outside the definition — but the same guidance tells institutions not to leave that judgment to the researcher, which is precisely why Walden routes it through the board.
  3. You receive a set with identifiers fully removed and no key at all. The people may no longer be subjects in the federal sense. Walden still reads the project; the file's job is to prove the de-identification actually happened, by whose hand, and against which standard.

Notice what runs through all three: the determination hangs on facts about other people — who abstracts, who keys, who signs — that you must arrange before you can describe them. A file that says "the data will be de-identified" without naming the person doing it has not answered the question, only restated it.

Which review path can an existing-records project take?

The Common Rule carves out secondary research at 45 CFR 46.104(d)(4): identifiable information already in existence can qualify for exemption when it is publicly available, or when it is recorded so that identities cannot readily be reached, with no contact and no re-identification by the researcher. Where the source is a HIPAA-regulated provider, a separate limb of the same exemption leans on HIPAA's own protections instead. Which of these, if any, fits your project — and whether the outcome is an exemption, an expedited reading, or something else — is the board's determination under Walden's current handbook and IRB portal, never a box you tick yourself. What each path asks of a file, and why chasing the label is the wrong way to draft, is the subject of our reading of Walden's exempt, expedited and full-board paths.

What does HIPAA add when the source is a clinical site?

If the records live at a hospital, clinic, or practice, the site is almost certainly a covered entity, and it cannot lawfully hand you patient information just because it likes your project. The Privacy Rule gives it a short menu, and your Walden file must name which item the site is using — in the site's words, not yours.

The site's lawful pathWhat it meansWhat your Walden file shows
Patient authorizationEach person whose chart is used signs for this specific research use — rarely workable for a retrospective sampleThe authorization language, and the honest reason this path was or wasn't chosen
Waiver of authorization under 45 CFR 164.512(i)An IRB or privacy board finds the identifiers protected, destroyed as early as the work allows, and the study impracticable otherwiseWhich board granted the waiver, its letter, and how your plan honors the findings it made
Limited data set, released under 45 CFR 164.514(e)Direct identifiers come out; dates and limited geography may stay; the recipient signs the accompanying data use agreement — to safeguard, not re-identify, and not contact anyoneThe agreement draft, who signs it on each side, and where its terms surface in your security plan
De-identified dataEvery category on the safe-harbor list is gone — names, the date elements on HIPAA's list, record and account numbers, and the catch-all for any other unique code — or an expert has certified the risk as very smallWho performed the de-identification, by which method, and confirmation nothing on the list survived
Review preparatory to researchReading charts to scope the design and gauge how many meet criteria, with nothing leaving the siteNothing yet — this path supports feasibility, and it is not collection

One quiet trap deserves its own sentence: a spreadsheet that keeps admission dates is not de-identified under safe harbor no matter how many names were deleted, because date elements sit on the list. The honest label for that file is a limited data set, and the agreement that travels with one belongs in your planning from the start.

What does the Walden file itself have to carry?

Walden's review opens with Form A, where the data sources and any partner organizations are described; on Walden's current process the IRB office then tells you which documents your particular sources call for. For a records project, expect the file to establish, in some form:

Where do records files actually go wrong?

Rarely on the science. The returns we see are alignment failures: an application that claims de-identified data while requesting a field list with birth dates in it; a permission letter authorizing "a review of outcomes" for a project whose plan names staffing records too; an honest-broker arrangement described in the application but absent from any signed page; a feasibility count performed by pulling charts before any letter existed. Each of these is visible at the desk before the board sees it, which is the argument for a desk-side reading that mirrors the board's — once, before filing. That reading, and everything after it, is what the practice carries end to end.

What to do next

Tell us what the records are, where they live, and who owns them — that is enough for a first reading. We are independent consultants, not affiliated with Walden University; we prepare the determination case, the documents, and every reply to the board, while the study and its findings stay yours and the decision stays the board's. Request the free application review, or browse the questions we answer most often.

Sources

The reply envelope

the practice
consultants to Walden doctoral candidates
at the ethics step

To: the candidate whose proposal is signed, whose reviewer has concurred — and whose application hasn't gone in yet.

Request the free application review

We read what you have as the board will and tell you where it stands — including, when it is true, “file it as it stands.” Then we carry the whole process: every document, the submission, every reply, until the approval letter. No cost to begin, no obligation.

Fiona Castellan, DNP, APRN Senior IRB consultant online